Hi I'm Kate, community lead for @OpenMedicineHQ. Open access and free for everyone.
New York, NY
Joined February 2017
- Tweets10.5K
- Following180
- Followers3K
- Likes78K
Kate Sears retweeted
Finding a target is only the start.
Ahead of #ESMO26, 🧬🎯 ESCAT v2 grades the evidence for benefit and resistance.
What does this result change for the person sitting in front of us?
@Annals_Oncology @myESMO @BenWestphalen @GPentheroudakis @quimmateo @OncoAlert @OpenMedicineHQ @Larvol @tompowles1
Kate Sears retweeted
Proud to be part of @OncoAlert . With the wealth of data coming out of #ESMO26 its helpful to have some select studies to key in on. Instead of taking one persons list we put together a group list based on Delphi consensus rules.
Immunotherapy and vaccine therapies clearly stealing the show, although still room for next generation targeted therapies too!
🚨 #ESMO26 GI Cancer: Top Ten by @OncoAlert 🧬
From organ preservation in dMMR rectal and gastric cancer to RAS(ON) inhibition in pancreatic cancer and bispecifics in biliary tract cancer, our faculty picked the must-know GI abstracts from Madrid 👇
#GICancer #CRCSM
@CathyEngMD, @BenWestphalen, @graokane, @NiuSanford, @GillSharlene, @pashtoonkasi, @DrVilmaPBarcia, @Erman_Akkus, @GIMedOnc, @UOzkerim, @MarioBalsaMD, @p_ciracimd, @DraMartinezLago, @DaisukeKotani, @Aiims1742, @ARosen380, @realbowtiedoc, @KoheiShitara , @pashtoonkasi
, @GillSharlene
Kate Sears retweeted
Sharing experiences and learning together...
⭐️ Open Medicine Algorithm Spotlight ⭐️
Daraxonrasib Toxicity Prevention and Management in Pancreatic Cancer from @DrShubhamPant and
@GIcancerDoc:
myopenmedicine.com/algorithm…
Kate Sears retweeted
How to start dermatologic prophylaxis before first dose, Daraxonrasib Toxicity Prevention and Management in Pancreatic Cancer from @DrShubhamPant and
@GIcancerDoc:
Kate Sears retweeted
Ten abstracts that will shape lung cancer practice, picked by our faculty 🫁
Stand-outs for me: DeLLphi-305 moving tarlatamab into 1L maintenance, and the head-to-head KRAS G12C data in Krascendo 1. Do not skip DIAL either: it asks whether we can safely stop IO at 6 months 👇 #ESMO26 #LCSM #LungCancer
🚨 #ESMO26 Lung Cancer: Top Ten by @OncoAlert 🫁
The abstracts our faculty picked as must-know from Madrid 👇
1️⃣ DeLLphi-305 (LBA3): tarlatamab + durvalumab, 1L maintenance in ES-SCLC
2️⃣ Krascendo 1 (LBA5): divarasib vs sotorasib/adagrasib in KRAS G12C NSCLC
3️⃣ SAFFRON (LBA6): osimertinib + savolitinib in EGFRm MET+ NSCLC post-osimertinib
4️⃣ OptiTROP-Lung04 (LBA67): final OS, sac-TMT vs chemo after EGFR-TKI
5️⃣ OptiTROP-Lung06 (LBA66): sac-TMT + pembro, 1L PD-L1-negative non-squamous NSCLC
6️⃣ PERSEE (2614O): pembro ± chemo, 1L PD-L1 ≥50%
7️⃣ SANOVO (LBA69): savolitinib + osimertinib, 1L EGFRm MET-overexpressed NSCLC
8️⃣ IFCT-2103 DIAL (2618RO): continue pembro vs observation at 6 months
9️⃣ PANKU-Lung01 (LBA71): iza-bren after third-generation EGFR TKI
🔟 SARON (2613O): consolidation radiotherapy in oligometastatic NSCLC
#lcsm #OncoAlert #MedTwitter
Pinging our OncoAlert Lung Cancer Faculty
@christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD
@peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @LeciaSequist @bensolomon1 @VanitaNoronha +@alexdrilon @JordiRemon @caliraf @JulienMazieres @TerriConneran
Kate Sears retweeted
⭐️ Open Medicine Algorithm Spotlight ⭐️
Locally advanced and metastatic Cutaneous Squamous Cell Carcinoma (cSCC) from @OmidHamidMD @angelesclinic:
myopenmedicine.com/algorithm…
Kate Sears retweeted
⭐️ Open Medicine Algorithm Spotlight ⭐️
Daraxonrasib Toxicity Prevention and Management in Pancreatic Cancer from @DrShubhamPant and
@GIcancerDoc:
myopenmedicine.com/algorithm…
Kate Sears retweeted
What a fantastic, practical and free resource for using Daraxonrasib! Even has a patient handout!!! Love it!
⭐️ Open Medicine Algorithm Spotlight ⭐️
Daraxonrasib Toxicity Prevention and Management in Pancreatic Cancer from @DrShubhamPant and
@GIcancerDoc:
myopenmedicine.com/algorithm…
Kate Sears retweeted
Very proud of @TheIACH satellite symposium at #ASH26
Please join us in-person or virtually.
apps.hematology.org/go/am26/…
apps.hematology.org/go/am26/…
@mvmateos @COMyCongress @NBahlis @ZamagniElena
Kate Sears retweeted
Getting ready for @myesmo #ESMO26?
Here are the top ten #LCSM presentations by @oncoalert
@SclcSMASHERS @FDA @LUNGevity @lungoncdoc @StephenVLiu @HHorinouchi @g_mountzios @sands_jacob @LauraAlderMD @oncodaily @OncoAlert @Latinamd @LuisPaz_Ares @RManochakian @LuisRaezMD @triparnasen @LaurenByersMD @LungCancerEu @alissajcooper @BZhangMD @NaglaAKarimMD @Annechiangmd @IASLC @NCCN @ASCO #ESMO26 @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @colazagasti @openmedicineHQ @myesmo @openmedkate @openmedben @chadinabhan @YoungLungCancer @OncodailyLung @ClinicalLung #LCSM @LungPolicy @dan_morgxen
🚨 #ESMO26 Lung Cancer: Top Ten by @OncoAlert 🫁
The abstracts our faculty picked as must-know from Madrid 👇
1️⃣ DeLLphi-305 (LBA3): tarlatamab + durvalumab, 1L maintenance in ES-SCLC
2️⃣ Krascendo 1 (LBA5): divarasib vs sotorasib/adagrasib in KRAS G12C NSCLC
3️⃣ SAFFRON (LBA6): osimertinib + savolitinib in EGFRm MET+ NSCLC post-osimertinib
4️⃣ OptiTROP-Lung04 (LBA67): final OS, sac-TMT vs chemo after EGFR-TKI
5️⃣ OptiTROP-Lung06 (LBA66): sac-TMT + pembro, 1L PD-L1-negative non-squamous NSCLC
6️⃣ PERSEE (2614O): pembro ± chemo, 1L PD-L1 ≥50%
7️⃣ SANOVO (LBA69): savolitinib + osimertinib, 1L EGFRm MET-overexpressed NSCLC
8️⃣ IFCT-2103 DIAL (2618RO): continue pembro vs observation at 6 months
9️⃣ PANKU-Lung01 (LBA71): iza-bren after third-generation EGFR TKI
🔟 SARON (2613O): consolidation radiotherapy in oligometastatic NSCLC
#lcsm #OncoAlert #MedTwitter
Pinging our OncoAlert Lung Cancer Faculty
@christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD
@peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @LeciaSequist @bensolomon1 @VanitaNoronha +@alexdrilon @JordiRemon @caliraf @JulienMazieres @TerriConneran
Kate Sears retweeted
Thanks Kate
Hope to see you in Madrid
Great algorithm. Very timely
@ArndtVogel @MyriamChalabi @OncoAlert @OncBrothers @UsuarezMD @Uromigos @VincentRK @JoshuaRichterMD
⭐️ Open Medicine Algorithm Spotlight ⭐️
Daraxonrasib Toxicity Prevention and Management in Pancreatic Cancer from @DrShubhamPant and
@GIcancerDoc:
myopenmedicine.com/algorithm…
Kate Sears retweeted
Thank you @DrShubhamPant @GIcancerDoc for your developing such an innovative and pragmatic guide to using Daraxonrasib. I know this will increase efficacy and decrease toxicities.
Thanks to @drallysonocean @allisonoconn @MPishvaian @GIMedOnc @YJanjigianMD (@myESMO chair) and all our GI faculty
We are determined to help improve care in both community and academic centres globally. We need to focus on prevention and early intervention.
Thanks to @letswinpc @KRASKickers and everyone working so hard here
@BenSasse for his braveness in telling his story @FiercePharma @statnews @endpts
Would love people’s comments on how we can improve this further. What else would you like to see?
Thanks to our amazing faculty. Hope to thank you in person soon @GlopesMd @montypal @AlisonBirtle @StephenVLiu @neerajaiims
⭐️ Open Medicine Algorithm Spotlight ⭐️
Daraxonrasib Toxicity Prevention and Management in Pancreatic Cancer from @DrShubhamPant and
@GIcancerDoc:
myopenmedicine.com/algorithm…
Kate Sears retweeted
These algorithms are incredibly helpful for unpacking best practices buried in manuscripts and institutional knowledge.
⭐️ Open Medicine Algorithm Spotlight ⭐️
Daraxonrasib Toxicity Prevention and Management in Pancreatic Cancer from @DrShubhamPant and
@GIcancerDoc:
myopenmedicine.com/algorithm…
Kate Sears retweeted
As @RajaFlores points out, oncology has a language problem, including how to define "early stage". cancerletter.com/perspective…
For patients & families "early stage" sounds reassuring:
✅ Caught early
✅ Treated
✅ Cured
But in #lungcancer, even stages I and II have a significant risk of recurrence. I know firsthand how devastating it is to be diagnosed with Stage Ia, believe I'm cured, experience recurrence, and learn I have advanced-stage disease.
Of course staging matters. But stage is not a prognosis, and patients aren't statistics. For patients and families, the real question is, "What does that stage mean for me, my family, my life?"
Because understanding your stage is not the same as understanding your cancer.
#LCSM #WordsMatter #staging @TheCancerLetter @DrewMoghanaki
Kate Sears retweeted
Why are clinical trials so expensive? In part, this 🤦🏽♂️
Whether "sodium chloride 0.9%" even needs to be a con-med is story for another day...
But to have this many back-and-forth CRO queries over "TKO" prevents data coordinators from working on anything else!
In a word, oof.
Hi friends, it's #BreastCancer Tuesday1 #ESMO26 edition 🎉🎉🎉
Here are Top Posts of the Week 🧵
1/ @PTarantinoMD on increased pCR with PD1-blockade + carbo/taxotere for TNBC:
xitter.cf/PTarantinoMD/status/21…
In @Annals_Oncology, results from a new phase 3 trial (HELEN Trio011 🇨🇳) showing improved pCR with PD1-blockade added to carbo/taxotere for TNBC. Together with NeoPACT, these results offer an alternative, anthracycline-sparing neoadjuvant regimen for TNBC. annalsofoncology.org/article…
5/ @Icro_Meattini on combining RT and ADCs in breast cancer:
xitter.cf/Icro_Meattini/status/2…
Safety of combining #radiotherapy and antibody-drug conjugates in patients with #breastcancer: a systematic review and meta-analysis
@RO_GreenJournal @ESTRO_RT @OncoAlert
#OncoAlert #radonc #medonc
thegreenjournal.com/article/…
Love #MedTwitter but not the noise? Get practice changing updates from social media.
Subscribe to our weekly newsletter and join your colleagues. Sign up free!
my.medical.watch